Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2025-07-17 Transaction in Own Shar…
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
Transaction in Own Shares Classification · 1% confidence The document is a semi-annual report on a liquidity contract (bilan semestriel du contrat de liquidité) for Theranexus. This type of disclosure relates to the company's share repurchase and market-making activities conducted by a third party (Portzamparc). Under the provided definitions, 'Transaction in Own Shares' (POS) is the most accurate category for reports detailing share buybacks, liquidity contracts, and related treasury share movements.
2025-07-17 French
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2025
Net Asset Value Classification · 1% confidence The document is a short press release (under 5,000 characters) announcing the company's cash position as of a specific date. It provides a summary of financial liquidity and mentions upcoming financial publication dates. It does not constitute a full financial report, but rather a periodic update on financial status, which falls under the category of general regulatory announcements or financial updates that do not fit into more specific categories like 10-K or IR. Given the nature of the announcement regarding cash position and financial visibility, it is best classified as a Regulatory Filing (RNS).
2025-07-10 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 JUIN 2025
Earnings Release Classification · 1% confidence The document is a short press release (under 5,000 characters) announcing the company's cash position as of June 30, 2025. It provides a brief financial update and mentions the date for the upcoming half-year results. It does not constitute a full financial report, but rather a periodic update on liquidity, which falls under the category of general regulatory announcements or financial updates that do not fit into more specific categories like 10-K or IR. Given the nature of the announcement as a corporate update, 'RNS' (Regulatory Filings) is the most appropriate classification. H1 2025
2025-07-10 French
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-WORLD DATA SUPPORTING BATTEN-1 EFFICACY FOR THE TREATMENT OF BATTEN DISEASE
Regulatory Filings Classification · 1% confidence The document is a press release dated May 13, 2025, announcing 'strong positive real-world data supporting Batten-1 efficacy' for treating Batten disease. It details clinical findings, quotes executives and external experts, and mentions future presentation plans (NCL 2025 Conference). This format—a formal announcement of significant business/clinical progress, often released outside of mandatory SEC filing cycles—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on clinical/data updates rather than management changes (MANG) or capital structure (CAP), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general announcement. Given the content is a major data announcement, it functions similarly to an ER announcing positive trial results, even if not strictly quarterly earnings. However, since the primary focus is announcing new data/results, and it is structured as a press release, it aligns closely with the function of an Earnings Release (ER) which often includes key operational/clinical highlights, or potentially a Regulatory Filing (RNS) if it were less specific. Given the high-impact nature of the data announcement, ER is a strong candidate, but RNS is the safest general category for non-standard, non-periodic announcements. Since it is a press release announcing significant operational/clinical progress, and it is not a formal report itself, I will classify it as an Earnings Release (ER) as it serves the function of communicating key performance indicators (clinical efficacy) to the market, which is often bundled with ERs for biotech firms. If ER is too specific, RNS is the fallback. Given the structure, ER is more descriptive of the intent than RNS.
2025-05-13 English
THERANEXUS ET LA FONDATION BEYOND BATTEN DISEASE ANNONCENT DES DONNÉES EN VIE RÉELLE TRÈS POSITIVES SOUTENANT L'EFFICACITÉ DE BATTEN-1 DANS LE TRAITEMENT DE LA MALADIE DE BATTEN CLN3
Earnings Release Classification · 1% confidence The document is a press release dated May 13, 2025, announcing 'très positives' real-world data supporting the efficacy of Batten-1 for treating CLN3 disease. It details statistical findings, quotes executives and medical professionals, and mentions future presentation at a conference (NCL 2025). This format—a formal announcement of recent scientific/clinical results intended for investors and the public—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it is not a full financial report (10-K/IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it focuses on clinical data/results, it best fits the 'Earnings Release' category, which often encompasses major operational or clinical milestones announced via press release, even if not strictly quarterly earnings. Given the context of a biopharma company announcing clinical data, ER is the most appropriate fit among the provided options for a major, time-sensitive announcement. Q2 2025
2025-05-13 French
URD 2024
Audit Report / Information Classification · 1% confidence The document is explicitly titled "DOCUMENT D'ENREGISTREMENT UNIVERSEL" (Universal Registration Document) and mentions its filing date (29/04/2025) and reference number with the AMF (Autorité des Marchés Financiers, the French financial regulator). This type of comprehensive annual filing, which incorporates previous years' financial data and risk factors, aligns directly with the definition of a major regulatory filing that serves as the basis for public offerings or listing. In the context of the provided codes, the closest equivalent to a comprehensive annual registration document, especially one that incorporates prior annual reports (as indicated by the incorporation by reference sections), is the Annual Report (10-K). However, since this is a specific European/French regulatory document ('Document d'Enregistrement Universel' or URD), and given the options, it functions as the primary annual disclosure document. While '10-K' is the US equivalent, the URD is the comprehensive annual filing. Given the extensive nature (570k characters) and the detailed table of contents covering risk factors, company history, and business overview, it is a full annual disclosure, making '10-K' the most appropriate classification among the choices for a comprehensive annual report, even if the specific document name is French. If 'URD' were an option, it would be preferred, but 10-K serves as the proxy for the main annual filing. FY 2024
2025-04-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.